nach oben

Journal of Neuro-Oncology

Erschienen in:

01.04.2008 | lab investigation-human/animal tissue

Vincristine and lomustine induce apoptosis and p21^WAF1 up-regulation in medulloblastoma and normal human epithelial and fibroblast cells

verfasst von: Zakia Shinwari, Pulicat S. Manogaran, Salman A. Alrokayan, Khaled A. Al-Hussein, Abdelilah Aboussekhra

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Medulloblastomas arise in the cerebellum and are the most common pediatric primary malignant brain tumors. Currently, medulloblastoma patients are best treated with surgical removal of the tumor, adjuvant radiation therapy and chemotherapy. The chemotherapeutic agents that showed efficiency against medulloblastomas include lomustine and vincristine. However, the effects of these drugs on medulloblastomas as well as on other cell types is still not well defined. In the present report we present evidence that the cytotoxic effect of these drugs is not specific for medulloblastoma cells but includes also normal fibroblast and epithelial cells. We have also shown that vincristine and lomustine trigger apoptosis in all these cells through the mitochondrial pathway via decrease in the level of the anti-apoptosis proteins Bcl-2 and Bcl-xl, respectively. Intriguingly, the proportion of apoptotic cells induced in medulloblastoma and normal epithelial and fibroblastic cells was similar. In addition, vincristine induced low proportion of necrosis in medulloblastoma and normal fibroblast cells. Interestingly, while vincristine induced cell cycle delay in G2/M phase in normal as well as medulloblastoma cells, lomustine effect on the cell cycle was specific for medulloblastoma cells. Furthermore, we have shown that vincristine and lomustine up-regulated p21 protein level in a p53-independent manner. These results shed more light on the biological effects of vincristine and lomustine and show that lomustine is a more specific and potent anti-medulloblastoma agent.

Gurney JG, Kadan-Lottick N (2001) Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr Opin Oncol 13:160–166PubMedCrossRef

Jozwiak J, Grajkowska W, Wlodarski P (2006) Pathogenesis of medulloblastoma and current treatment outlook. Med Res Rev 6:6

Rood BR, Macdonald TJ, Packer RJ (2004) Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol 31:666–675PubMedCrossRef

Brown JM, Attardi LD (2005) The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5:231–237PubMedCrossRef

Reed JC (2003) Apoptosis-targeted therapies for cancer. Cancer Cell 3:17–22PubMedCrossRef

Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108:153–164PubMedCrossRef

Wu GS, El-Deiry WS (1996) Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or Bcl-2. Clin Cancer Res 2:623–633PubMed

Schulze-Bergkamen H, Krammer PH (2004) Apoptosis in cancer—implications for therapy. Semin Oncol 31:90–119PubMedCrossRef

Fulda S, Debatin KM (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25:4798–4811PubMedCrossRef

10.

Norbury CJ, Zhivotovsky B (2004) DNA damage-induced apoptosis. Oncogene 23:2797–2808PubMedCrossRef

11.

Cory S, Adams JM (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2:647–656PubMedCrossRef

12.

Willis SN, Adams JM (2005) Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 17:617–625PubMedCrossRef

13.

Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME, Debatin KM (1998) Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-irradiation-induced apoptosis of brain tumor cells. Cell Death Differ 5:884–893PubMedCrossRef

14.

Soini Y, Paakko P, Lehto VP (1998) Histopathological evaluation of apoptosis in cancer. Am J Pathol 153:1041–1053PubMed

15.

Haslam RH, Lamborn KR, Becker LE, Israel MA (1998) Tumor cell apoptosis present at diagnosis may predict treatment outcome for patients with medulloblastoma. J Pediatr Hematol Oncol 20:520–527PubMedCrossRef

16.

Pizem J, Cor A, Zadravec Zaletel L, Popovic M (2005) Prognostic significance of apoptosis in medulloblastoma. Neurosci Lett 381:69–73PubMedCrossRef

17.

Pingoud-Meier C, Lang D, Janss AJ, Rorke LB, Phillips PC, Shalaby T, Grotzer MA (2003) Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res 9:6401–6409PubMed

18.

Zong WX, Thompson CB (2006) Necrotic death as a cell fate. Genes Dev 20:1–15PubMedCrossRef

19.

Jaattela M (2004) Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 23:2746–2756PubMedCrossRef

20.

Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB (2004) Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 18:1272–1282PubMedCrossRef

21.

Packer RJ, Goldwein J, Nicholson HS, Vezina LG, Allen JC, Ris MD, Muraszko K, Rorke LB, Wara WM, Cohen BH, Boyett JM (1999) Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group Study. J Clin Oncol 17:2127–2136PubMed

22.

Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, Mulne L, Boyett J, D’Angio G, Wechsler-Jentzsch K et al (1994) Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81:690–698PubMedCrossRef

23.

Rutkauskiene G, Labanauskas L (2005) Treatment of patients of high-risk group of medulloblastoma with the adjuvant lomustine, cisplatin, and vincristine chemotherapy. Medicina (Kaunas) 41:1026–1034

24.

Lefkowitz IB, Packer RJ, Siegel KR, Sutton LN, Schut L, Evans AE (1990) Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine. Cancer 65:412–417PubMedCrossRef

25.

Raffel C, Thomas GA, Tishler DM, Lassoff S, Allen JC (1993) Absence of p53 mutations in childhood central nervous system primitive neuroectodermal tumors. Neurosurgery 33:301–305PubMedCrossRef

26.

Lu X, Lane DP (1993) Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 75:765–778PubMedCrossRef

27.

Di Leonardo A, Linke SP, Clarkin K, Wahl GM (1994) DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8:2540–2551PubMedCrossRef

28.

Lakin ND, Jackson SP (1999) Regulation of p53 in response to DNA damage. Oncogene 18:7644–7655PubMedCrossRef

29.

El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825PubMedCrossRef

30.

Gartel AL, Tyner AL (1999) Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 246:280–289PubMedCrossRef

31.

Al-Mohanna MA, Al-Khalaf HH, Al-Yousef N, Aboussekhra A (2007) The p16INK4a tumor suppressor controls p21WAF1 induction in response to ultraviolet light. Nucleic Acids Res 35:223–233PubMedCrossRef

32.

Ellison DW, Clifford SC, Gajjar A, Gilbertson RJ (2003) What’s new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol 7:53–66PubMedCrossRef

33.

Kartner N, Riordan JR, Ling V (1983) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221:1285–1288PubMedCrossRef

34.

Schinkel AH, Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3–29PubMedCrossRef

35.

Johnson DR, Finch RA, Lin ZP, Zeiss CJ, Sartorelli AC (2001) The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice. Cancer Res 61:1469–1476PubMed

36.

Balayssac D, Cayre A, Authier N, Bourdu S, Penault-Llorca F, Gillet JP, Maublant J, Eschalier A, Coudore F (2005) Patterns of P-glycoprotein activity in the nervous system during vincristine-induced neuropathy in rats. J Peripher Nerv Syst 10:301–310PubMedCrossRef

37.

Gnewuch CT, Sosnovsky G (1997) A critical appraisal of the evolution of N-nitrosoureas as anticancer drugs. Chem Rev 97:829–1014PubMedCrossRef

38.

Legha SS (1986) Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1:421–427PubMed

39.

Gidding CE, Kellie SJ, Kamps WA, de Graaf SS (1999) Vincristine revisited. Crit Rev Oncol Hematol 29:267–287PubMedCrossRef

40.

Scheithauer W, Ludwig H, Maida E (1985) Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report. Invest New Drugs 3:315–318PubMedCrossRef

41.

Merimsky O, Loewenstein A, Chaitchik S (1992) Cortical blindness—a catastrophic side effect of vincristine. Anticancer Drugs 3:371–373PubMedCrossRef

42.

Aisner J, Weiss HD, Chang P, Wiernik PH (1974) Orthostatic hypotension during combination chemotherapy with vincristine (NSC-67574). Cancer Chemother Rep 58:927–930PubMed

43.

Boyle FM, Eller SL, Grossman SA (2004) Penetration of intra-arterially administered vincristine in experimental brain tumor. Neuro Oncol 6:300–305PubMedCrossRef

44.

Sui M, Fan W (2005) Combination of gamma-radiation antagonizes the cytotoxic effects of vincristine and vinblastine on both mitotic arrest and apoptosis. Int J Radiat Oncol Biol Phys 61:1151–1158PubMed

45.

Kumar KS, Sonnemann J, Hong le TT, Buurman C, Adler F, Maass M, Volker U, Beck JF (2007) Histone deacetylase inhibitors, but not vincristine, cooperate with radiotherapy to induce cell death in medulloblastoma. Anticancer Res 27:465–470PubMed

46.

Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N, Graf N, Emser A, Pietsch T, Wolff JE, Kortmann RD, Kuehl J (2005) Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352:978–986PubMedCrossRef

47.

Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, Bayer L, LaFond D, Donahue BR, Marymont MH, Muraszko K, Langston J, Sposto R (2006) Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24:4202–4208PubMedCrossRef

48.

Cakar M, Aksoy S, Kilickap S, Harputluoglu H, Erman M (2005) Procarbazine, lomustine, vincristine combination may be effective in adult medulloblastoma patients with systemic metastases. J Neurooncol 75:233–234PubMedCrossRef

49.

Fan S, Cherney B, Reinhold W, Rucker K, O’Connor PM (1998) Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clin Cancer Res 4:1047–1054PubMed

50.

Rohn TA, Wagenknecht B, Roth W, Naumann U, Gulbins E, Krammer PH, Walczak H, Weller M (2001) CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene 20:4128–4137PubMedCrossRef

51.

Haapajarvi T, Kivinen L, Heiskanen A, des Bordes C, Datto MB, Wang XF, Laiho M (1999) UV radiation is a transcriptional inducer of p21(Cip1/Waf1) cyclin-kinase inhibitor in a p53-independent manner. Exp Cell Res 248:272–279PubMedCrossRef

Titel: Vincristine and lomustine induce apoptosis and p21WAF1 up-regulation in medulloblastoma and normal human epithelial and fibroblast cells
verfasst von: Zakia Shinwari
Pulicat S. Manogaran
Salman A. Alrokayan
Khaled A. Al-Hussein
Abdelilah Aboussekhra
Publikationsdatum: 01.04.2008
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2008
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-007-9502-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Section on Tumors Biennial Meeting April 13–14, 2007 Washington, DC

Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database

Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas

Prognostic factors in breast cancer patients with brain metastases

Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients